Posted on October 16, 2008 by crimsoncanary
Cytopia Limited are to present data on its JAK2 inhibitor program at two important scientific meetings this month – the Hematological Society of Australia and New Zealand and the ‘Drug Discovery on Target’ conference in Boston USA
Filed under: Uncategorized | Tagged: Cytopia, JAK2 | Comments Off
Posted on October 15, 2008 by crimsoncanary
SuperGen are to present data on the following kinase inhibitors at the 20th EORTC-NCI-AACR Symposium
Abstract 403, 426: MP-470, multikinase inhibitor
Abstract 332: SGI-1776, PIM kinase inhibitor
Abstract 571: SGI-1252, JAK2 kinase inhibitor
Filed under: Uncategorized | Tagged: JAK2, kinase, MP-470, mp470, PIM, sgi-1252, SGI-1776, sgi1252, SGI1776, Supergen | Comments Off
Posted on September 18, 2008 by crimsoncanary
Incyte have reported positive results from Phase IIa clinical trials of JAK2 inhibitor INCB18424 in patients with mild to moderate psoriasis.
Filed under: kinase | Tagged: INCB-18424, INCB18424, Incyte, JAK2, kinase, Phase IIa | Comments Off
Posted on September 18, 2008 by crimsoncanary
S*BIO Pte have announced the initiation of multi-center Phase I clinical trials of JAK2 inhibitor SB1518 in patients with leukemia and certain types of lymphoma.
Filed under: Uncategorized | Tagged: JAK2, kinase, s bio, SB-1518, SB1518, sbio | Comments Off
Posted on September 5, 2008 by crimsoncanary
AstraZenecas AZ960 inhibits JAK2 with a Ki of 0.00045 µM in vitro and demostrates apoptic activity in cell based assays
Filed under: kinase | Tagged: AstraZeneca, AZ-960, AZ960, JAK2, kinase | Comments Off
Posted on September 4, 2008 by crimsoncanary
S*Bio have initated a Phase I/II trial of JAK2 inhibitor SB1518 in Chronic Idiopathic Myelofibrosis diseases including Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera and Essential Thrombocythemia
Filed under: kinase | Tagged: JAK2, kinase, s bio, SB-1518, SB1518, sbio | Comments Off
Posted on August 12, 2008 by crimsoncanary
Cytopia have announced that it will be presenting data on its JAK2 program at the Philadelphia ACS meeting.
Filed under: kinase | Tagged: Cytopia, JAK2, kinase | Comments Off
Posted on July 30, 2008 by crimsoncanary
In 2nd quarter results Incyte have provided an update on JAK2 inhibitors INC18424 and INCB28050
Filed under: kinase | Tagged: INCB-18424, INCB-28050, INCB18424, INCB28050, Incyte, JAK, JAK2, kinase | Comments Off
Posted on July 29, 2008 by crimsoncanary
Cytopia have appointed a Study chair at the Mayo Clinic in preparation of Phase I JAK2 trials for myelofibrosis
Filed under: kinase | Tagged: Cytopia, JAK2, phase I | Comments Off
Posted on June 16, 2008 by crimsoncanary
Data presented at the European Hematology Association show SuperGen’s JAK2 inhibitor SGI-1252 to inhibitor tumor cell proliferation in mouse xenograft models.
Filed under: kinase | Tagged: JAK-2, JAK2, kinase, Preclinical, Research, Supergen | Comments Off
